Literature DB >> 17564423

P2Y1 antagonists: combining receptor-based modeling and QSAR for a quantitative prediction of the biological activity based on consensus scoring.

Stefano Costanzi1, Irina G Tikhonova, Michihiro Ohno, Eun Joo Roh, Bhalchandra V Joshi, Anny-Odile Colson, Dayle Houston, Savitri Maddileti, T Kendall Harden, Kenneth A Jacobson.   

Abstract

P2Y1 is an ADP-activated G protein-coupled receptor (GPCR). Its antagonists impede platelet aggregation in vivo and are potential antithrombotic agents. Combining ligand and structure-based modeling we generated a consensus model (LIST-CM) correlating antagonist structures with their potencies. We docked 45 antagonists into our rhodopsin-based human P2Y1 homology model and calculated docking scores and free binding energies with the Linear Interaction Energy (LIE) method in continuum-solvent. The resulting alignment was also used to build QSAR based on CoMFA, CoMSIA, and molecular descriptors. To benefit from the strength of each technique and compensate for their limitations, we generated our LIST-CM with a PLS regression based on the predictions of each methodology. A test set featuring untested substituents was synthesized and assayed in inhibition of 2-MeSADP-stimulated PLC activity and in radioligand binding. LIST-CM outperformed internal and external predictivity of any individual model to predict accurately the potency of 75% of the test set.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17564423     DOI: 10.1021/jm0700971

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  18 in total

Review 1.  Nucleotides Acting at P2Y Receptors: Connecting Structure and Function.

Authors:  Kenneth A Jacobson; Silvia Paoletta; Vsevolod Katritch; Beili Wu; Zhan-Guo Gao; Qiang Zhao; Raymond C Stevens; Evgeny Kiselev
Journal:  Mol Pharmacol       Date:  2015-04-02       Impact factor: 4.436

2.  Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligands.

Authors:  Stefano Costanzi; Irina G Tikhonova; T Kendall Harden; Kenneth A Jacobson
Journal:  J Comput Aided Mol Des       Date:  2008-05-16       Impact factor: 3.686

3.  Ligand and structure-based models for the prediction of ligand-receptor affinities and virtual screenings: Development and application to the beta(2)-adrenergic receptor.

Authors:  Santiago Vilar; Joel Karpiak; Stefano Costanzi
Journal:  J Comput Chem       Date:  2010-03       Impact factor: 3.376

Review 4.  P2Y nucleotide receptors: promise of therapeutic applications.

Authors:  Kenneth A Jacobson; Jean-Marie Boeynaems
Journal:  Drug Discov Today       Date:  2010-06-02       Impact factor: 7.851

5.  Pharmacochemistry of the platelet purinergic receptors.

Authors:  Kenneth A Jacobson; Francesca Deflorian; Shilpi Mishra; Stefano Costanzi
Journal:  Purinergic Signal       Date:  2011-02-18       Impact factor: 3.765

Review 6.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

7.  Demystifying P2Y1 Receptor Ligand Recognition through Docking and Molecular Dynamics Analyses.

Authors:  Antonella Ciancetta; Robert D O'Connor; Silvia Paoletta; Kenneth A Jacobson
Journal:  J Chem Inf Model       Date:  2017-11-28       Impact factor: 4.956

8.  Predicting the biological activities through QSAR analysis and docking-based scoring.

Authors:  Santiago Vilar; Stefano Costanzi
Journal:  Methods Mol Biol       Date:  2012

9.  On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor.

Authors:  Stefano Costanzi
Journal:  J Med Chem       Date:  2008-04-29       Impact factor: 7.446

10.  Development of selective agonists and antagonists of P2Y receptors.

Authors:  Kenneth A Jacobson; Andrei A Ivanov; Sonia de Castro; T Kendall Harden; Hyojin Ko
Journal:  Purinergic Signal       Date:  2008-07-04       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.